You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股收評:三大指數漲跌不一,滬指漲0.2%,教育股、國資改革概念股大漲

5月27日,A股三大指數漲跌不一,滬指早盤高位盤整,午後跳水翻綠,收盤漲0.23%報3130點,深成指跌0.12%,盤中一度漲2.4%的創業板指最終收漲0.06%。兩市1866股上漲,2620股下跌,成交額8158億元,北上資金淨買入39億元。 滬指周跌0.52%,深成指周跌2.28%,創業板指周跌3.92%。

行業板塊多數下跌,科技板塊跌幅靠前,教育、石油股大漲,中國海油、傳智教育等多股漲停,中國石油漲超3%;醫藥股走勢分化,CXO概念大漲,藥明康德漲5%;汽車股、煤炭股延續近期強勢,國資改革概念股狂掀漲停潮種業、水利建設、裝配式建築、航運等概念活躍

教育板塊強勢走高。豆神教育、昂立教育、中國高科、傳智教育、凱文教育、國新文化漲停,、學大教育、全通教育漲超6%,中公教育漲超5%。

消息面上,教育部辦公廳近日印發通知,部署加強小學科學教師培養,鼓勵高水平師範院校整合校內外優質資源開設科學教育專業。

油氣板塊漲幅居前。中國海油漲停,股價創上市新高,淮油股份漲停,仁智股份、中曼石油漲超54%,通源石油、潛能恆信漲超3%。

消息面上,由於美國原油和汽油庫存下降加劇夏季需求高峯燃料短缺,擔心歐盟將很快通過分階段石油禁令,隔夜歐美原油期貨大幅度上漲,布倫特原油期貨漲至兩個月來最高價位。

央企國資改革板塊狂掀漲停潮。中汽股份、國投中魯、航天晨光、英力特、東風科技、中交地產、錢江水利、中天火箭等20股漲停。

消息面上,中航電子、中航機電兩大軍工央企宣佈重組。中信建投指出,隨着國企改革三年行動計劃進入收官階段,後續改革案例有望繼續湧現。

CRO板塊漲幅明顯。皓元醫藥漲超13%,百花村漲停,凱萊英、康龍化成漲超6%,和元生物漲超5%,藥明康德漲超4%。

今年2月8日,美國商務部工業與安全局(BIS)掛網公開了更新的“未經證實名單(Unverified List,簡稱UVL)”,其中藥明生物和藥明生物(上海)就在其列,這在當時給了CRO企業一記重擊。昨晚,美國國務卿布林肯發表對華政策演講時稱美國決心避免與中國發生“新冷戰”,市場或認為這對此前受創的CRO企業是個好消息。

汽車板塊延續近期漲勢。中通客車11連板,安凱客車、亞星客車漲停,金龍汽車逼近漲停。中集車輛漲超4%。

消息面上,汽車行業利好政策不斷。國辦支持國外消費者購買中國品牌汽車。國常會近日提出階段性減徵部分乘用車購置税600億元及其他多項利好汽車行業恢復和發展的政策。浙江等多個省份出台促汽車消費政策,深圳新增投放2萬個普通小汽車增量指標,對購置新能源汽車的中籤者給予最高不超過2萬元/台補貼。

水利板塊表現活躍。錢江水利、湖南發展、浙江建投、誠邦股份漲停,粵水電、華建集團、漲超7%。

消息面上,發改委等三部門印發《“十四五”城市排水防澇體系建設行動計劃》提出,系統建設城市排水防澇工程體系,加快推進河道堤防、護岸等城市防洪工程建設。

個股異動方面,新華製藥再度漲停,收穫5天4板,股價再創歷史新高,近21個交易日累計漲幅超310%。消息面上,近日,新華製藥收到了匈牙利藥監部門(OGYÉI)頒發的歐盟GMP證書。至此,新華製藥現代醫藥國際合作中心已通過中國NMPA、英國MHRA、美國FDA和歐盟等GMP認證。新華製藥現代醫藥國際合作中心生產的製劑產品具備了銷往歐、美、英等高端國際市場的資格。

北向資金方面,北上資金淨流入72.72億元,其中滬股通淨流入56.61億元,深股通淨流入16.11億元。

展望後市,招商證券策略團隊認為,隨着國內疫情得到控制,政治局會議強調的已出台和正謀劃的“增量政策工具”有望落地推進,投資項目落地開工,將帶動社融重回上行,改善市場經濟預期,A股有望逐漸企穩回升,逐漸走向新一輪上行週期起點。

行業配置方面關注兩大方向,第一,穩增長方向。,第二,疫後經濟活動恢復。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account